2012
DOI: 10.1007/s11240-012-0249-z
|View full text |Cite
|
Sign up to set email alerts
|

Glycomodification and characterization of anti-colorectal cancer immunotherapeutic monoclonal antibodies in transgenic tobacco

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
30
0

Year Published

2013
2013
2024
2024

Publication Types

Select...
4
2
2

Relationship

3
5

Authors

Journals

citations
Cited by 26 publications
(34 citation statements)
references
References 37 publications
1
30
0
Order By: Relevance
“…Many plant-derived recombinant pharmaceutical proteins have been produced in transgenic tobacco plant and were extracted directly from harvested leaves because this plant is well established in the expression of a non-food/feed crop, and its high biomass yields and rapid scalability for molecular biofarming (Ko et al, 2005;Lee et al, 2013;Lu et al, 2012;So et al, 2012). Tobacco has been widely adopted as a model system by several biotech companies (Accardi and Di Bonito, 2010;Twyman et al, 2003).…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…Many plant-derived recombinant pharmaceutical proteins have been produced in transgenic tobacco plant and were extracted directly from harvested leaves because this plant is well established in the expression of a non-food/feed crop, and its high biomass yields and rapid scalability for molecular biofarming (Ko et al, 2005;Lee et al, 2013;Lu et al, 2012;So et al, 2012). Tobacco has been widely adopted as a model system by several biotech companies (Accardi and Di Bonito, 2010;Twyman et al, 2003).…”
Section: Resultsmentioning
confidence: 99%
“…Another advantage of plant-system is that recombinant vaccine candidates can be expressed in edible plant organ tissues (Frutos et al, 2008;Ma et al, 2003;Matsuda and Kubota, 2010). To this day, various horticultural crops, along with tobacco and Arabidopsis thaliana (Arabidopsis), have been used in bioreactors for producing vaccines (Lu et al, 2012), antibodies (Lee et al, 2013;So et al, 2012), and various other pharmaceutical proteins (Stoger et al, 2005). In general, recombinant biopharmaceutical proteins are expressed and accumulated in soluble forms in plant biomass, thus, produced total soluble protein (TSP).…”
Section: Introductionmentioning
confidence: 99%
“…These results suggest that the ER retention signal KDEL retains GA733-Fc in the ER without secretion to CM (in the absence of the signal peptide, the default secretion pathway was not followed). Attachment of KDEL has been used to enhance production of recombinant proteins with oligomannose glycan structure in animal, plant and insect cells (Henderson et al 1996;Schouten et al 1996;Lee et al 2013;So et al 2013;Kim et al 2015;Lim et al 2015). Oligomannose can enhance an immune response because of the interaction between oligomannose of glycoproteins and the mannose receptor on macrophages and dendritic cells.…”
Section: Discussionmentioning
confidence: 99%
“…; So et al . ). KDEL is an endoplasmic reticulum (ER) retention signal that can be used to retrieve proteins from a subsequent compartment of the secretory pathway and return them to the ER (Munro & Pelham ; Pelham , ; Ellgaard et al .…”
Section: Introductionmentioning
confidence: 97%
“…In a previous study, a pFastBacDual vector was employed to carry the gene encoding the light and heavy chains of mAb CO17-1A under the control of the P10 (PP10) and polyhedrin promoters (PPH), respectively. The recombinant antibodies were processed, modified and targeted to their appropriate subcellular locations, including secretion to intracellular spaces (Ko et al 2003;Xing et al 2009;So et al 2013). KDEL is an endoplasmic reticulum (ER) retention signal that can be used to retrieve proteins from a subsequent compartment of the secretory pathway and return them to the ER (Munro & Pelham 1987;Pelham 1988Pelham , 1990Ellgaard et al 1999).…”
Section: Introductionmentioning
confidence: 99%